Picture of Bioventix logo

BVXP — Bioventix News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Posting of Annual Report and Notice of AGM


		
		
		
		
		
		
	
	
RNS Number : 2182C
BioVentix PLC
06 November 2026
 

Bioventix plc

("Bioventix" or the "Company")

 

Posting of Annual Report and Notice of AGM

 

Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has posted its Annual Report for the year ended 30 June 2026 together with a Notice of Annual General Meeting ("AGM") and Form of Proxy to shareholders that have elected to receive documentation in hard copy format. The documents will also be available from the Company's website at www.bioventix.com under the Investors section.

 

The Company's AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 3 December 2026 at 2.00pm.

 

For further information please contact:

Bioventix plc


 

Tel: 01252 728 001

Peter Harrison

Chief Executive Officer


 


 


 


 

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash/Elysia Bough

Corporate Finance


 

Nigel Birks/Harriet Ward

ECM


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAZQLFBQFLZFBE

Recent news on Bioventix

See all news